Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development

Kelloff, Gary J., Krohn, Kenneth A., Larson, Steven M., Weissleder, Ralph, Mankoff, David A., Hoffman, John M., Link, Jeanne M., Guyton, Kathryn Z., Eckelman, William C., Scher, Howard I., O'Shaughnessy, Joyce, Cheson, Bruce D., Sigman, Caroline C., Tatum, James L., Mills, George Q., Sullivan, Daniel C., Woodcock, Janet·2005·Clinical Cancer Research

Abstract

As addressed by the recent Food and Drug Administration Critical Path Initiative, tools are urgently needed to increase the speed, efficiency, and cost-effectiveness of drug development for cancer and other diseases. Molecular imaging probes developed based on recent scientific advances have great potential as oncologic drug development tools. Basic science studies using molecular imaging probes can help to identify and characterize disease-specific targets for oncologic drug therapy. Imaging end points, based on these disease-specific biomarkers, hold great promise to better define, stratify, and enrich study groups and to provide direct biological measures of response. Imaging-based biomarkers also have promise for speeding drug evaluation by supplementing or replacing preclinical and clinical pharmacokinetic and pharmacodynamic evaluations, including target interaction and modulation. Such analyses may be particularly valuable in early comparative studies among candidates designed to interact with the same molecular target. Finally, as response biomarkers, imaging end points that characterize tumor vitality, growth, or apoptosis can also serve as early surrogates of therapy success. This article outlines the scientific basis of oncology imaging probes and presents examples of probes that could facilitate progress. The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-1302

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 220

Metadata

Authors
Kelloff, G. J., Krohn, K. A., Larson, S. M., Weissleder, R., Mankoff, D. A., Hoffman, J. M., Link, J. M., Guyton, K. Z., Eckelman, W. C., Scher, H. I., O'Shaughnessy, J., Cheson, B. D., Sigman, C. C., Tatum, J. L., Mills, G. Q., Sullivan, D. C., & Woodcock, J.
Venue
Clinical Cancer Research
Published
2005-11-15
Volume
11
Issue
22
Pages
7967-7985
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2169813047
Cited by
220
References
5
FWCI
20.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-1302
The paper
Kelloff, G. J., Krohn, K. A., Larson, S. M., Weissleder, R., Mankoff, D. A., Hoffman, J. M., Link, J. M., Guyton, K. Z., Eckelman, W. C., Scher, H. I., O'Shaughnessy, J., Cheson, B. D., Sigman, C. C., Tatum, J. L., Mills, G. Q., Sullivan, D. C., & Woodcock, J. (2005). The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-1302

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.